Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7247669 plus platinum-based chemotherapy versus pembrolizumab plus platinum-based chemotherapy in previously untreated advanced or metastatic NSCLC
2022-001440-18Phase 2Active
- Sponsor
- Roche
- Start
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tobemstomig and pembrolizumab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Roche. Primary endpoint: Progression-free survival. Started Jul 2022; status: active.
02
Drugs
tobemstomigpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-001440-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001440-18.